Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

0.4410 -0.0134 (-2.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 482,993
Open 0.4400
Bid (Size) 0.4450 (52)
Ask (Size) 0.4550 (23)
Prev. Close 0.4544
Today's Range 0.4350 - 0.4553
52wk Range 0.2235 - 2.150
Shares Outstanding 149,339,335
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
From Affimed N.V.
Via GlobeNewswire
Recap: Affimed Q3 Earnings
Via Benzinga

Performance

YTD
-63.55%
-63.55%
1 Month
+9.73%
+9.73%
3 Month
-18.03%
-18.03%
6 Month
-41.59%
-41.59%
1 Year
-79.20%
-79.20%

More News

Read More
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Earnings Outlook For Affimed
Via Benzinga
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
From Affimed N.V.
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Affimed
Via Benzinga
Expert Ratings for Affimed
Via Benzinga
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
From Affimed N.V.
Via GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Where Affimed Stands With Analysts
Via Benzinga
Affimed Earnings Preview
Via Benzinga
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed to Participate in Upcoming Investor Conferences
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Listing Transfer to Nasdaq Capital Markets
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Cantor Global Healthcare Conference 2023
From Affimed N.V.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
From Affimed N.V.
Via GlobeNewswire
Surprise! These 3 Penny Stocks Have Wall Street’s Seal of Approval.
Via InvestorPlace
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
3 Cheap Stocks to Buy Under $1 in August 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.